134 related articles for article (PubMed ID: 9138100)
1. Plasma level monitoring of nasal salmon calcitonin in the rat by a heterogeneous two-site enzyme immunoassay.
Nakamuta H; Kohno T; Ichikawa M; Hoshino T; Watabe K; Koida M
J Clin Lab Anal; 1997; 11(3):129-31. PubMed ID: 9138100
[TBL] [Abstract][Full Text] [Related]
2. A noncompetitive enzyme immunoassay (hetero-two-site enzyme immunoassay) for salmon calcitonin: determination of the bioavailability of subcutaneous salmon calcitonin and its correlation with the hypocalcemic activity in rats.
Kohno T; Nakamuta H; Ichikawa M; Watabe K; Koida M
J Clin Lab Anal; 1996; 10(2):91-7. PubMed ID: 8852361
[TBL] [Abstract][Full Text] [Related]
3. A sandwich transfer enzyme immunoassay for salmon calcitonin: determination of the bioavailability of intranasal salmon calcitonin in human.
Kohno T; Murasugi N; Sakurai H; Watabe K; Nakamuta H; Koida M; Sugie Y; Nomura M; Yanagawa A
J Clin Lab Anal; 1997; 11(6):380-7. PubMed ID: 9406061
[TBL] [Abstract][Full Text] [Related]
4. Pharmacologic evaluation of the calcitonin analogue SB 205614 in models of osteoclastic bone resorption in vitro and in vivo: comparison with salmon calcitonin and elcatonin.
McSheehy PM; Farina C; Airaghi R; Allievi E; Banfi S; Bertolini D; Ferni G; Frattola D; Oneta S; Pinza M
Bone; 1995 Apr; 16(4):435-44. PubMed ID: 7605704
[TBL] [Abstract][Full Text] [Related]
5. Histomorphometrical evaluation of anti-osteopenic effect of nasal salmon calcitonin in a type 1 osteoporotic model of rats.
Nitta T; Hoshino T; Koida M; Nakamuta H
Biol Pharm Bull; 1996 Feb; 19(2):214-6. PubMed ID: 8850308
[TBL] [Abstract][Full Text] [Related]
6. Anti-osteopenic effect of nasal salmon calcitonin in type 1 osteoporotic rats: comparison with subcutaneous dosing.
Ichikawa M; Nakamuta H; Hoshino T; Ogawa Y; Koida M
Biol Pharm Bull; 1994 Jul; 17(7):911-3. PubMed ID: 8000375
[TBL] [Abstract][Full Text] [Related]
7. Intrapulmonary drug delivery of salmon calcitonin.
Deftos LJ; Nolan JJ; Seely BL; Clopton PL; Cote GJ; Whitham CL; Florek LJ; Christensen TA; Hill MR
Calcif Tissue Int; 1997 Oct; 61(4):345-7. PubMed ID: 9312206
[TBL] [Abstract][Full Text] [Related]
8. Effect of chitosan on the intranasal absorption of salmon calcitonin in sheep.
Hinchcliffe M; Jabbal-Gill I; Smith A
J Pharm Pharmacol; 2005 Jun; 57(6):681-7. PubMed ID: 15969922
[TBL] [Abstract][Full Text] [Related]
9. Intranasal delivery of PEGylated salmon calcitonins: hypocalcemic effects in rats.
Lee KC; Park MO; Na DH; Youn YS; Lee SD; Yoo SD; Lee HS; DeLuca PP
Calcif Tissue Int; 2003 Dec; 73(6):545-9. PubMed ID: 14508623
[TBL] [Abstract][Full Text] [Related]
10. Determination of the bioavailability of intranasal elcatonin in humans: development of a sandwich transfer enzyme immunoassay for elcatonin.
Kohno T; Murasugi N; Sakurai H; Watabe K; Nakamuta H; Koida M; Sugie Y; Ogouchi T; Inoue T; Yanaka M; Nomura M; Yanagawa A
J Clin Lab Anal; 1998; 12(6):356-62. PubMed ID: 9850187
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of modified oral calcitonin product in healthy volunteers.
Chin CM; Gutierrez M; Still JG; Kosutic G
Pharmacotherapy; 2004 Aug; 24(8):994-1001. PubMed ID: 15338848
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of nasal salmon calcitonin absorption by lauroylcarnitine chloride in rats.
Kagatani S; Shinoda T; Fukui M; Ohmura T; Hasumi S; Sonobe T
Pharm Res; 1996 May; 13(5):739-43. PubMed ID: 8860430
[TBL] [Abstract][Full Text] [Related]
13. Optimizing bioavailability of oral administration of small peptides through pharmacokinetic and pharmacodynamic parameters: the effect of water and timing of meal intake on oral delivery of Salmon Calcitonin.
Karsdal MA; Byrjalsen I; Riis BJ; Christiansen C
BMC Clin Pharmacol; 2008 Sep; 8():5. PubMed ID: 18782439
[TBL] [Abstract][Full Text] [Related]
14. Effect of nasal salmon calcitonin on calcium and bone metabolism.
Thamsborg G
Dan Med Bull; 1999 Apr; 46(2):118-26. PubMed ID: 10327295
[TBL] [Abstract][Full Text] [Related]
15. Design of salmon calcitonin particles for nasal delivery using spray-drying and novel supercritical fluid-assisted spray-drying processes.
Cho W; Kim MS; Jung MS; Park J; Cha KH; Kim JS; Park HJ; Alhalaweh A; Velaga SP; Hwang SJ
Int J Pharm; 2015 Jan; 478(1):288-296. PubMed ID: 25445994
[TBL] [Abstract][Full Text] [Related]
16. An acute and focal osteopenia model using ovariectomized rats: a rapid detection of the protective effect of salmon calcitonin.
Nakamuta H; Sasaki M; Ichikawa M; Koida M
Biol Pharm Bull; 1993 Mar; 16(3):325-7. PubMed ID: 8364484
[TBL] [Abstract][Full Text] [Related]
17. Bone-anabolic effect of salmon calcitonin on glucocorticoid-induced osteopenia in rats.
Furuichi H; Fukuyama R; Izumo N; Fujita T; Kohno T; Nakamuta H; Koida M
Biol Pharm Bull; 2000 Aug; 23(8):946-51. PubMed ID: 10963301
[TBL] [Abstract][Full Text] [Related]
18. Encapsulation into PEG-liposomes does not improve the bioavailability of pulmonary delivered salmon calcitonin.
Swaminathan J; Gobbo OL; Tewes F; Healy AM; Ehrhardt C
J Aerosol Med Pulm Drug Deliv; 2014 Feb; 27(1):1-11. PubMed ID: 24252061
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of nasal and intestinal calcitonin delivery by the novel Pheroid fatty acid based delivery system, and by N-trimethyl chitosan chloride.
du Plessis LH; Lubbe J; Strauss T; Kotzé AF
Int J Pharm; 2010 Jan; 385(1-2):181-6. PubMed ID: 19854253
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of gelatin microspheres for nasal and intramuscular administrations of salmon calcitonin.
Morimoto K; Katsumata H; Yabuta T; Iwanaga K; Kakemi M; Tabata Y; Ikada Y
Eur J Pharm Sci; 2001 May; 13(2):179-85. PubMed ID: 11297902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
